Vendor profile Research · US · —

Xingruida XDR

B+
Composite 7.7 / 10

Last updated 2026-10-12. Composite is computed from the live database; missing sub-scores redistribute weight across the others.

Lab quality
6.4
Fair
Sentiment
—
—
COA
—
Limited
Reliability
—
— tenure
Pricing
9.8
Verified

Peptide breakdown

PeptideScoreLab qualityTestsPurity Qty var.$/mg verifiedLast testRanking
Retatrutide
8.4B+
8.0 30 — — — — view
Tirzepatide
8.3B+
7.9 24 — — — — view
Ipamorelin
7.9B+
7.4 3 — — — — view
GHK-Cu
7.7B+
7.1 9 — — — — view
BPC-157
6.2C
5.3 8 — — — — view
Tesamorelin
6.2C
5.4 10 — — — — view
PT-141
5.9C
5.9 3 — — — — view
TB-500
5.3C
4.2 3 — — — — view
CJC-1295
—
— 0 — — — — view
Semaglutide
—
— 0 — — — — view

COA transparency

  • ○ Publishes per-batch COAs (not just one COA for everyone) (pending)
  • ○ Both HPLC and mass spec shown (pending)
  • ○ Endotoxin or sterility data shown (pending)
  • ○ At least one COA independently cross-checked (pending)
  • ○ Most recent COA within 90 days (pending)
All vendor grades, side-by-side
Compare Xingruida XDR against every other vendor in the grade hub →
Top-5 ranked vendors per peptide, plus the highest-rated vendors overall. Daily refresh.